Short answer
Astrana Health, Inc. (ASTH) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation for conference and meeting use, signaling refreshed investor messaging.
Astrana Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation for conference and meeting use, signaling refreshed investor messaging
- Exhibit 99.1 contains the substantive presentation materials and may include updated strategy or operating information
- Information furnished under Regulation FD, limiting its treatment as a formal Exchange Act filing
- No obligation to update presentation content, increasing risk that disclosed information may become outdated
Item EX-99.1 · Exhibit EX-99.1
- FY2026 revenue guidance $3.8–4.1B and Adjusted EBITDA guidance $255–280M, midpoint $267.5M
- 2026E Adjusted EBITDA margin 6.8%, with targeted mid-to-high teens annual growth over the medium term
- Approximately 1.5M value-based members, 20,000+ providers, 20+ payer partners across 18 markets
- Full-risk arrangements generated 81% of Q2 2026 capitation revenue, increasing exposure to both upside and medical-cost risk
- G&A improved 210 basis points year over year to 5.6% in Q2 2026, supporting operating leverage
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Astrana Health, Inc. 8-K filings
Get the next ASTH 8-K as it lands
Follow ASTH for push alerts, or ask the research agent what this filing means.